]>
IRCT20200907048644N1 IRCT 2020-10-04 Zahedan University of Medical Sciences Celecoxib effects on COVID-19 patients Evaluation of short-term effects of Celecoxib on clinical improvement of COVID-19 patients: A randomized clinical trial study 2020-09-22 anticipated 60 Complete https://irct.ir/trial/50932 interventional Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Single, Purpose: Treatment, Randomization description: Based on previous studies calculating the sample size for interventional studies, 60 adult patients with moderate COVID-19 (hospitalized in the general ward) are randomly divided into two groups by permutation block method. So that the two groups are matched to the variables of age and sex. 1 COVID-19. Intervention 1: Intervention group: 40 patients receiving routine + celecoxib treatments. This group is divided into two subgroups (20 people in each group):A dose received 200mg / day (in divided doses)B at a dose of 400mg / day (in divided doses). Intervention 2: Control group: 20 subjects with routine therapy. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is It hasnt been designed.
public Roghayh Sheervalilou
Dr. Hesabi roundabout
Zahedan Iran (Islamic Republic of) 9816743463 +98 54 3329 5817 sheervalilour@tbzmed.ac.ir Zahedan University of Medical Sciences scientific Dr. Habib Ghaznavi
Dr. Hesabi roundabout, Zahedan
Zahedan Iran (Islamic Republic of) 9816743463 +98 54 3320 5705 ghaznavih@yahoo.com Zahedan University of Medical Sciences Iran (Islamic Republic of) Iran (Islamic Republic of) Subjects with COVID-19 in the second phase of the disease Shortness of breath, chest pain with or without fever equal to or greater than 38 'C Blood oxygen saturation (SpO2) between 90-93% Adult patients with COVID-19 with moderate pulmonary involvement and hospitalized in the general ward who have been diagnosed and confirmed with coronavirus by conventional diagnostic methods such as sequencing or qRT-PCR and CT (within 48 hours of admission) Age range of patients between 18-65 years Existence of pneumonia in lung CT scan with involvement of maximum 3 or 4 lung lobes or less than one third of the volume of each lobe or infection of one or two lobes with larger area Patients informed consent 18 years 65 years Both Patients under 18 or over 65 years old Patients with severe and advanced disease are admitted to the intensive care unit Participate in another clinical trial Shock and critical illness (requires ventilator and organ failure) Patients with organ dysfunction such as renal failure and liver damage, patients with asthma Taking certain medications such as furosemide or Lasex, lithium, ACE2 inhibitors Pregnancy People with medical history such as high blood pressure, autoimmune diseases and .. U07.1 COVID-19 Treatment - Drugs Treatment - Drugs Intervention group: 40 patients receiving routine + celecoxib treatments. This group is divided into two subgroups (20 people in each group):A dose received 200mg / day (in divided doses)B at a dose of 400mg / day (in divided doses) Control group: 20 subjects with routine therapy Lung function (Pulmonary infiltration, GGO, Edema). Timepoint: Every week. Method of measurement: CT Scan. Respiratory Rate, SpO2, PaO2/FiO2. Timepoint: Every day. Method of measurement: Physical examination. Body Temperature. Timepoint: Every day. Method of measurement: Thermometer. Zahedan University of Medical Sciences Approved 2020-08-26 Zahedan University of Medical Sciences Dr. Hesabi Zahedan Sistan-va-Balouchestan Iran (Islamic Republic of)